ICON plc’s Post

Check out this article in ACRP - Association of Clinical Research Professionals where our very own Chris B. highlights the importance of converting raw data from investigator meetings into actionable insights. With the right technology partner, turning data into impactful metrics is seamless, bridging gaps between study teams and stakeholders. Read the rest of the article to discover how to make your data work for you!

Discover ways to bridge gaps between study teams and tech providers for better outcomes in a recent ACRP blog > https://bit.ly/4df7Z58 Chris Bryant of Array highlights the need for the pharmaceutical industry to optimize metrics and utilize technology to convert data from investigator meetings into meaningful strategies. The full article will be available in the upcoming August 2024 issue of ACRP's Clinical Researcher Journal. #ClinicalResearch #ClinicalTrials #ClinicalResearcher #Pharma

We do our diligence. That's why James Gilligan, MSIB, PhD and Deepak Behera, MD, key members of Bracken's M&A Advisory team, are headed to the 43rd Annual #JPMorganHealthcareConference next week.   Book a time to connect with our experts before the conference, and learn firsthand how Bracken brings unmatched expertise across pharmaceutical and radiopharmaceutical assets, clinical service providers, and technology platforms supporting pharma, biotech, and imaging companies—delivering the depth and breadth you need for a successful transaction.   Learn more about Bracken's M&A Advisory expertise here: https://lnkd.in/g8U3-d9H   #JPM #JPM2025 #DueDiligence #MergersAndAcquisitions #Regulatory #ClinicalDevelopment #Biotech #Radiopharmaceuticals #LifeScience #Bracken

CVCT in Washington, D.C. – Lots to learn and exchange with regulatory bodies, MedTech, Biotech, and pharmaceutical industry representatives, former clinical academic colleagues, current and future customers, partners, and investigators. There even is a wine and cheese poster presentation session. Great to be here! #CVCT24 #ClinicalResearch #RegulatoryAffairs #HealthcareIndustry #CardiovascularResearch

We are just a few days before publishing the 2024 Access to Medicine Index - the 9th iteration - on 19 November! #access2meds The need for equitable access to medicines has never been more urgent, given the increasing burden of non-communicable diseases around the world, the rise of resistant infections and the threat of further pandemics. Innovative medical treatments can help address these challenges and radically improve global health – but they must be made available to all. In the 2024 Index we unpack how 20 of the largest R&D-based pharma companies are providing access to their products in low- and middle-income countries #LMICs. The report further highlights the practical steps that companies can take to give more people in LMICs the affordable medicines they need – from vaccines against infections to treatments for diabetes and cancer. 

Important for beginners to learn Computer Aided Drug Design and Discovery methods.

Proud to share my recent publication in the European Journal of Pharmaceutical and Medical Research: 'Virtual Trials: How COVID-19 Has Transformed Clinical Research, this paper explores how the pandemic accelerated the shift to virtual methods in clinical trials, paving the way for a blended approach in the future. Read about the impact of virtual trials and the opportunities for remote and in-person integration in clinical research. https://lnkd.in/dtGy9j97 #ClinicalResearch #VirtualTrials #PharmaceuticalResearch #COVID19Impac

🚀Short video interview series #ExploreWithJeeva episode 1 of 14 is Live! Pharmaceutical Outsourcing asked our Founder, What do we mean by modern clinical trials and how they differ from traditional ones? Harsha K Rajasimha shares his vision on how Hybrid and Decentralized Clinical Trials (DCTs) are set to revolutionize the landscape of conventional clinical research methodologies. Tune in now and be part of the conversation! 🎧✨ https://lnkd.in/gH4f9hjh   #clinicaltrials #decentralizedtrials #DCTs #jeevaclinicaltrials #biotech #medicalresearch

How far has the #pharma industry come since 2022? And what’s next? The 2022 Access to Medicine Index #ATMI22 revealed promising steps forward: more pharmaceutical companies stepped up to make some of their products more widely accessible in low- and middle-income countries #LMICs. Will the industry now go further? The 2024 Access to Medicine Index #ATMI24, coming out on 19 November, will reveal new insights, showcasing recent industry shifts and highlighting opportunities to close persistent gaps and accelerate progress toward achieving global #HealthEquity. Read the 2022 #AccesstoMedicine Index ➡ https://lnkd.in/ei5ayAuu #EquitableAccess #AccesstoHealthcare #GlobalHealth

An excellent paper from experts representing both the Development CMC Regulatory and CMC Speed to Market workstreams. 🌟 I can’t wait to see what is undoubtedly an industry-changing initiative!